How many drugs treat Mantle cell lymphoma?

Drug Landscape tracks 10 marketed treatments for Mantle cell lymphoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/mantle-cell-lymphoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Mantle cell lymphoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mantle cell lymphoma (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Mantle cell lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Brukinsa	BGB-3111	Beigene Usa Inc	Kinase Inhibitor [EPC]	Tyrosine-protein kinase BTK	2019-01-01
Calquence	ACALABRUTINIB	AstraZeneca	Kinase Inhibitor [EPC]	Tyrosine-protein kinase BTK	2017-01-01
Imbruvica	ibrutinib	AbbVie	Kinase Inhibitor [EPC]	Tyrosine-protein kinase Blk	2013-01-01
Torisel	temsirolimus	Pfizer	Kinase Inhibitor	Serine/threonine-protein kinase mTOR	2007-01-01
Revlimid	lenalidomide	Bristol-Myers Squibb	Thalidomide analogue	Cereblon (component of cullin ring E3 ubiquitin ligase enzyme complex)	2005-01-01
Velcade	bortezomib	Shilpa	Proteasome inhibitor	26S proteasome chymotrypsin-like activity	2003-01-01
Fludara	FLUDARABINE PHOSPHATE	Nihon Schering K.K.	Nucleoside Metabolic Inhibitor	Carbonic anhydrase 5A, mitochondrial	1991-01-01
Revlimid	Revlimid	M.D. Anderson Cancer Center		Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor
Velcade	Velcade	University of Arkansas		26S proteasome non-ATPase regulatory subunit 1, PH and SEC7 domain-containing protein 1, Cathepsin G
Imbruvica	Imbruvica	Rabin Medical Center		Nuclear receptor subfamily 4 group A member 3, Platelet glycoprotein VI, Serine/threonine-protein kinase LATS1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AbbVie · 1 drug in Mantle cell lymphoma
AstraZeneca · 1 drug in Mantle cell lymphoma
Azienda Ospedaliera San Giovanni Battista · 1 drug in Mantle cell lymphoma
Beigene Usa Inc · 1 drug in Mantle cell lymphoma
Bristol-Myers Squibb · 1 drug in Mantle cell lymphoma
Celyad Oncology SA · 1 drug in Mantle cell lymphoma
M.D. Anderson Cancer Center · 1 drug in Mantle cell lymphoma
Nihon Schering K.K. · 1 drug in Mantle cell lymphoma
Pfizer · 1 drug in Mantle cell lymphoma
Rabin Medical Center · 1 drug in Mantle cell lymphoma
Shilpa · 1 drug in Mantle cell lymphoma
Singapore General Hospital · 1 drug in Mantle cell lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Mantle cell lymphoma:

Cite this brief

Drug Landscape (2026). Mantle cell lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/mantle-cell-lymphoma. Accessed 2026-06-10.

Mantle cell lymphoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing